Independent report · Healthcare

ChrysCapital and Linux Laboratories: US$70m of equity from ChrysCapital

· By Janvi

Kshitij Sheth, Managing Director of ChrysCapital · Image: Business Today

Kshitij Sheth, Managing Director of ChrysCapital · Image: Business Today

Independent report content

COMPANYLinux Laboratories Pvt Ltd, Chennai (not Mumbai), specialty formulations company founded 2007 · focus on brain care (epilepsy, neuropathic pain, depression, autism), plus dermatology, cardio-diabetes and nutraceuticals
DEALUS$70m of equity: a "significant minority" stake to ChrysCapital with Tata Capital Healthcare Fund III · primary plus secondary, split not disclosed · Tata Capital Healthcare Fund II exited fully at about 4x
PRE-DEAL REPORTS (9 SEP)20–25% for about ₹600 Cr (US$60–65m), from unnamed sources (Economic Times via Medical Dialogues); the final announcement gave no stake or valuation
OWNERSHIP BEFOREPromoters Keerthivasan K, Ananda Kumar Sundharam and Hariharan Parameswaran 84.68%; Fund II about 15.32%
FINANCIALSFY25 operating income ₹259 Cr (Medical Dialogues) or ₹285 Cr (Tofler summary) · profit ₹22–26 Cr · FY27 forecast ₹450–500 Cr revenue and ₹85–90 Cr EBITDA (unconfirmed, ET)
REACH60,000+ doctors, 1,000+ medical representatives, seven divisions, one WHO-GMP plant · 125+ brands (company) or 64+ (Medical Dialogues)
USE OF MONEYCore specialties, adjacent therapies, brand acquisitions, manufacturing and R&D
ADVISERSAvendus (per two outlets) or O3 Capital (one summary) for Linux; Cyril Amarchand Mangaldas for Linux; Shardul Amarchand Mangaldas for ChrysCapital
THE ACCESS POINT Linux Laboratories is private. Stake and valuation were not published. Access is only through its investors' funds, open to qualified investors.

Executive decision summary

THE BOTTOM LINEChrysCapital and Tata Capital Healthcare Fund III invested US$70 million in Linux Laboratories, a Chennai maker of brain-care and other specialty medicines, in an announcement reported between 29 September and 1 October 2026. The money buys a "significant minority" stake, mixes new shares with a sale by existing holders, and lets Tata Capital Healthcare Fund II exit at about four times its cost. The stake and the valuation were not disclosed in the final announcement; the only numbers are from unnamed-source reports on 9 September that spoke of 20–25% for about ₹600 crore. FY25 revenue is given as ₹259 crore or ₹285 crore depending on the source, so the price relative to earnings cannot be fixed. The deal is the second this year in which ChrysCapital has bought into Indian pharma, after agreeing in February to buy control of Novartis India (completion reported around July by Venture Intelligence).
WHICH INVESTORThe deal fits a study of private equity in branded pharma IF you want to see a minority-growth structure with a prior investor exiting. Wait IF you need the stake, valuation or audited accounts: none was published.
COMFORT FITMinority stake = a share below 50%, so the founders keep control. Primary and secondary = new shares for the company, and shares sold by existing investors. CNS = central nervous system: medicines for epilepsy, pain, depression and similar conditions. WHO-GMP = a manufacturing quality standard, so the plant can supply regulated and export markets.
THE RUPEIA NUMBER84.68% and 15.32%. The promoter and Fund II stakes before the deal, which add to exactly 100% and show that Fund II was the only outside shareholder.

1 CLAIM REGISTER: EVIDENCE GRADING

ClaimSourceGradeRupeia assessment
US$70m equity from ChrysCapital and Tata Capital Healthcare Fund IIIEntrepreneur India; DealStreetAsia; Lapaas VoiceBEstablished
Fund II exited about 4xEntrepreneur India; DealStreetAsiaCReported by two outlets
20–25% for about ₹600 Cr, pre-dealMedical Dialogues (9 Sep), unnamed sourcesDPre-deal report; final stake not published
FY25 operating income ₹259 Cr or ₹285 CrMedical Dialogues vs Tofler summaryDConflict; no audited filing opened
FY27 revenue ₹450–500 Cr, EBITDA ₹85–90 CrET via Medical DialoguesDForecast, unconfirmed
125+ brands vs 64+ brandsEntrepreneur; DealStreetAsia vs Medical DialoguesDConflict

2 THE DEAL

ItemDetail
AmountUS$70m of equity
InvestorsChrysCapital (significant minority stake) and Tata Capital Healthcare Fund III
StructurePrimary plus secondary from promoters and Fund II; split not disclosed (Shardul Amarchand Mangaldas note, 1 Oct)
ExitTata Capital Healthcare Fund II sells its entire holding, about 15.32% before the deal, at about 4x
DatesPre-deal report 9 Sep; company announcement 29 Sep; coverage 30 Sep to 1 Oct; advisers' notes 1 and 9 Oct
Use of moneyDeeper penetration in core specialties, adjacent therapies, brand acquisitions, manufacturing and R&D
Calculation (Rupeia)Result
Ownership check before the deal100% − 84.68% (promoters) = 15.32% (Fund II), matching Medical Dialogues
US$70m in rupees at ₹96.5About ₹676 Cr
Pre-deal valuation implied by ₹600 Cr for 20–25%₹2,400 Cr to ₹3,000 Cr
Valuation if US$70m bought 20–25%US$280m to US$350m, about ₹2,700–3,400 Cr (illustration; the final stake is not published)
Value Fund II realised if 15.32% was sold at ₹2,400–3,000 Cr₹368–460 Cr, about 4x a cost of ₹92–115 Cr (illustration, assumes ₹2,400–3,000 Cr valuation)
RUPEIA READ The 84.68% and 15.32% shares add to 100%, so before this deal Linux had exactly one outside shareholder, Fund II. That makes the structure unusually simple: the incoming money partly replaces the departing fund and partly goes to the company. The valuation is the missing piece. A US$70 million cheque for 20–25% implies about US$280–350 million, which is above the ₹2,400–3,000 crore implied by the pre-deal report, so either the stake or the primary size is smaller than reported.

3 THE COMPANY AND ITS NUMBERS

MeasureValueSource quality
FY25 operating income₹259 Cr (Medical Dialogues); revenue ₹285 Cr against ₹250 Cr in FY24 (Tofler summary)Conflicting
FY25 profit₹22 Cr (sign ambiguous) or ₹26 Cr against ₹17.7 Cr in FY24Conflicting
GrowthAbout 12.9% revenue growth (ThecompanyCheck snippet)Snippet
FY27 forecastRevenue ₹450–500 Cr; EBITDA ₹85–90 CrET via Medical Dialogues; unconfirmed
Brands and range125+ brands and about 400 SKUs, or 64+ brands and about 180 productsConflicting
Field force60,000+ doctors reached; 1,000+ medical representatives; seven divisionsEntrepreneur India
PlantOne WHO-GMP facility; exports and CDMO mentioned but not quantifiedEntrepreneur India
Acquired portfoliosBiomedica, Indiabulls Pharmaceuticals, brands from Cipla and Dr Reddy'sEntrepreneur India
Calculation (Rupeia)Result
FY25 profit margin₹22 Cr ÷ ₹259 Cr = 8.5%; ₹26 Cr ÷ ₹285 Cr = 9.1%
Revenue growth from FY24 ₹250 Cr₹259 Cr = +3.6%; ₹285 Cr = +14%; the 12.9% claim is close to the second
Growth implied by the FY27 forecast(₹450 Cr ÷ ₹285 Cr)^0.5 = +26% a year; (₹500 Cr ÷ ₹259 Cr)^0.5 = +39% a year
Forecast EBITDA margin₹85 Cr ÷ ₹450 Cr = 18.9%; ₹90 Cr ÷ ₹500 Cr = 18%
Price to sales and earnings at ₹2,400–3,000 Cr8.4x to 11.6x FY25 revenue; 92x to 136x FY25 profit; 27x to 35x FY27 forecast EBITDA
Doctors per medical representative60,000 ÷ 1,000 = 60
RUPEIA READ The forecast would require revenue to grow by about 26–39% a year for two years from a company that grew 4–14% last year. If the ET forecast is right, the deal prices Linux at about 27 to 35 times its FY27 EBITDA; if growth stays near last year's pace, the multiple on current earnings is above 90 times. That gap is the whole valuation debate, and it cannot be resolved without audited numbers.

4 THE INVESTORS AND THE CHRYSCAPITAL PHARMA BOOK

ItemDetailSource
ChrysCapital Fund XUS$2.2bn final close, announced 5 Nov 2025; Fund IX US$1.35bn (2022)Search summary; Entrackr
Pharma and healthcare allocationAbout 20–25% of Fund X, indicatively US$440–550m; Kshitij Sheth, Managing Director: "historically been overweight on pharma and healthcare"Business Today, 22 Sep 2026
Novartis India70.68% for about ₹1,446 Cr; agreement 19 Feb 2026 (Report 56)Press
StrategySelective control deals alongside minority deals; Sheth: "not going to move exclusively into control deals"Business Today
Tata Capital Healthcare Fund IIIAlso invested in Tenet Diagnostics in August 2026 (Report 58)DealStreetAsia
Calculation (Rupeia)Result
Fund X against Fund IXUS$2.2bn ÷ US$1.35bn − 1 = 63% larger
Pharma and healthcare allocation of Fund X20% × US$2.2bn = US$440m; 25% = US$550m
Two 2026 ChrysCapital pharma deals₹1,446 Cr (Novartis India, with partners) + about ₹676 Cr (Linux, with Tata Capital) ≈ ₹2,100 Cr
Linux cheque against the Fund X pharma allocationUS$70m ÷ US$440–550m = 13–16%, an upper bound because Tata Capital also invested

Search summaries gave post-open-offer holdings of WaveRise 72.78%, Fund X 17.33% and Two Infinity 6.57% for Novartis India. These add to 96.68%, which is 70.68% plus the 26% open offer, so they describe a fully accepted offer. The actual open offer drew almost no tenders (Report 56), so those figures should not be read as holdings.

RUPEIA READ ChrysCapital said that it expects 20% to 25% of Fund X to go to pharma and healthcare, and in 2026 it has already written two cheques in the sector. For a Fund X investor, the interesting question is how many more deals of this size the pharma allocation can hold, and whether they are control or minority.

5 SECTOR CONTEXT

DatapointDetailSource
Annual PE in Indian pharmaRose from US$800–900m to US$1.2–1.3bn over two to three years (one firm's estimate)Kshitij Sheth, Business Today
PE and VC in pharma and devices since 2016US$16.4bn across 303 deals; since 2021 US$10.2bn across 201 dealsEY
Q1 2026 pharma and healthcare deals78 deals, US$1.9bn, down 40% on the previous quarterGrant Thornton Bharat
Reported talksQuadria-led consortium and Samarth Lifesciences, 80–85% at about ₹4,500 CrSearch snippet; unverified
Calculation (Rupeia)Result
Growth in annual PE, midpoints(1.25 ÷ 0.85) − 1 = 47%
Average deal size since 2016US$16.4bn ÷ 303 = US$54m; since 2021 US$10.2bn ÷ 201 = US$51m
Share of value since 2021US$10.2bn ÷ US$16.4bn = 62%; the share of deals is 201 ÷ 303 = 66%
Q1 2026 average dealUS$1.9bn ÷ 78 = US$24m
RUPEIA READ The Linux cheque of US$70 million is above the sector's average deal of about US$50 million, which fits a mid-sized branded-pharma business with a clear brain-care franchise. It sits in a strong period of private-equity interest, though deal counts fell in the first quarter as big deals paused.

6 RISKS, SCENARIOS AND CHECKLIST

RiskEvidenceSeverityKill condition
Valuation unknownStake and price not published; pre-deal report conflicts with US$70mHIGHEntry price proves high
Financial disclosureFY25 revenue ₹259 Cr vs ₹285 Cr; profit sign ambiguousHIGHAudited accounts show weaker figures
Growth forecastFY27 forecast needs 26–39% a yearMEDIUMGrowth stays near 4–14%
Brand concentrationCNS-heavy domestic branded portfolioMEDIUMPrice controls or generic competition
Conflicting detailsBrand count, advisers and founder list differLOWCorporate records differ
Use of moneyNot quantifiedMEDIUMBrand purchases overpriced
ScenarioWhat happensOutcome
BullGrowth reaches forecast; acquisitions add brandsStrong growth platform
BaseGrowth near 15–20%; steady marginsModerate return
BearGrowth stays low and the price proves richWeak return
Investor classFitWhy
Healthcare fund investorWATCHDepends on Tata Capital Healthcare Fund III's entry terms
Pharma sector researcherFITClear example of a minority-growth structure
Retail investorNOT AVAILABLEPrivate company

Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. Open items are the stake, the valuation and audited FY25 and FY26 accounts.

7 KEY TERMS USED IN THIS REPORT

The terms below are used in this report. Each is explained in plain words.

TermMeaning
Minority stakeA holding below 50% that does not give control.
Primary and secondaryNew shares for the company versus shares sold by existing holders.
CNSCentral nervous system; medicines for brain and nerve conditions.
WHO-GMPA manufacturing quality standard set by the World Health Organization.
SKUStock-keeping unit: one distinct product pack.
CDMOContract development and manufacturing: making medicines for other companies.

Frequently asked questions

What did ChrysCapital invest in?

ChrysCapital and Tata Capital Healthcare Fund III put US$70 million of equity into Linux Laboratories, a Chennai specialty pharma company, for a significant minority stake.

What stake and valuation?

The final announcement did not give them. A pre-deal report on 9 September cited unnamed sources for 20–25% at about ₹600 crore.

Who sold?

Tata Capital Healthcare Fund II exited fully, reportedly at about four times its cost. Promoters also sold some shares.

What does Linux Laboratories do?

It sells specialty formulations, led by brain-care medicines for epilepsy, pain, depression and autism, plus dermatology, cardio-diabetes and nutraceuticals.

Where is it based?

Chennai. The research brief said Mumbai, but the sources place it in Chennai.

What does Linux earn?

FY25 operating income of ₹259 crore or revenue of ₹285 crore, depending on the source, with a profit of ₹22–26 crore. No audited accounts were opened.

Source log

Entrepreneur India: Linux Labs secures US$70 Mn from ChrysCapital, Tata Capital

DealStreetAsia: Linux Laboratories raises US$70m from ChrysCap, Tata Capital Healthcare Fund III

Medical Dialogues: ChrysCapital to acquire 20–25% stake in Linux Laboratories for around ₹600 cr

Venture Intelligence: ChrysCapital to acquire 25% stake in brain-care focused Linux Labs for US$65 m

Shardul Amarchand Mangaldas: advises ChrysCapital on acquisition of stake in Linux Laboratories

SCC Online: Linux Laboratories, ChrysCapital, Tata Capital Healthcare Fund III

Lapaas Voice: Linux Laboratories US$70m deal

Business Today: Why ChrysCapital expects 20–25% of the latest US$2.2 billion fund to go to pharma and healthcare

DISCLAIMER This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.